TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25332466

Group type: EXPERIMENTAL
Intervention: Biofortified beans (8.8 mg Fe, 1320 mg PA/100 g)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Biofortified beans with ∼50% dephytinization
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Biofortified beans with >95% dephytinization
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control beans (5.4 mg Fe, 980 mg PA/100 g)
Number of subjects: 22
Study: 22348455

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 20973735

Group type: EXPERIMENTAL
Intervention: T'ai chi exercise (TCE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional exercise (CE)
Number of subjects: 0
Study: 16602668

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg continuous daily therapy
Number of subjects: 1904

Group type: COMPARATOR
Intervention: Esomeprazole 20 mg on-demand treatment
Number of subjects: 1904
Study: 14597910

Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 14

Group type: COMPARATOR
Intervention: LCPUFA supplemented formula
Number of subjects: 14
Study: 11145325

Group type: EXPERIMENTAL
Intervention: Home sleep recording
Number of subjects: 16

Group type: COMPARATOR
Intervention: Laboratory polysomnography
Number of subjects: 16
Study: 9336333

Group type: EXPERIMENTAL
Intervention: Indomethacin (0.66 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Indomethacin (0, 0.17, 0.33, 0.66 and 1.33 mg/kg) with ethanol (0 and 1 g/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Indomethacin (0 and 0.66 mg/kg) with pentobarbital (0, 1.33 and 4 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (indomethacin)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (pentobarbital)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (ethanol)
Number of subjects: 10
Study: 1337362

Group type: EXPERIMENTAL
Intervention: 15 g of total dietary fiber as modified guar gum
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 15 g of total dietary fiber as soy polysaccharide
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 0 g of fiber (maltodextrin)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: self-selected diet
Number of subjects: 11
Study: 2937825

Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 533

Group type: COMPARATOR
Intervention: Control
Number of subjects: 533
Study: 31370830

Group type: EXPERIMENTAL
Intervention: Vegetable-exposure intervention
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Sensitive feeding intervention
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Combined intervention (vegetable-exposure + sensitive feeding)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 240
Study: 30324933

Group type: EXPERIMENTAL
Intervention: Pit and fissure sealant with chlorhexidine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Pit and fissure sealant without chlorhexidine
Number of subjects: 66
Study: 27169522

Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 23
Study: 25233346

Group type: EXPERIMENTAL
Intervention: Amphotericin B lipid emulsion (ABLE) 15 mg/kg single infusion
Number of subjects: 500

Group type: COMPARATOR
Intervention: Liposomal formulation (LAmB)
Number of subjects: 500
Study: 22842244

Group type: COMPARATOR
Intervention: Zinc phosphate cement
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resin-modified GIC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Adhesive resin cement
Number of subjects: 30
Study: 21164548

Group type: EXPERIMENTAL
Intervention: NUTRIOSE supplementation (17 g twice daily for 12 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Maltodextrin placebo (CONTROL GROUP)
Number of subjects: 60
Study: 18055891

Group type: EXPERIMENTAL
Intervention: Evidence summaries appended to discharge letters
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group (no evidence summaries)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Evidence summaries
Number of subjects: 178
Study: 16567150

Group type: EXPERIMENTAL
Intervention: 100% portion size
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 150% portion size
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 200% portion size
Number of subjects: 32
Study: 14593194

Group type: EXPERIMENTAL
Intervention: Gadofosveset (0.005, 0.01, 0.03, 0.05, or 0.07 mmol/kg)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Nonenhanced MR angiography
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Gadofosveset
Number of subjects: 238
Study: 11081237

Group type: EXPERIMENTAL
Intervention: Health-promotion lessons integrated into regular school lessons in the intervention school
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 0
Study: 8935341

Group type: EXPERIMENTAL
Intervention: 250 mg/day of terbinafine for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: 500 mg/day of terbinafine for 7 days during the first week of each month for 3 months
Number of subjects: 60
Study: 1287618

Group type: EXPERIMENTAL
Intervention: Cefaclor AF (375 mg twice daily)
Number of subjects: 1138

Group type: COMPARATOR
Intervention: Cefaclor (250 mg three times daily)
Number of subjects: 1138
Study: 3896555

Group type: COMPARATOR
Intervention: PAAP (azathioprine/antithymocyte globulin/prednisone)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CyA (cyclosporine and prednisone)
Number of subjects: 25
Study: 29801474

Group type: EXPERIMENTAL
Intervention: HF10 injection every 2 weeks for up to 4 times
Number of subjects: 12
Study: 27306560

Group type: EXPERIMENTAL
Intervention: Valsartan treatment for 4 weeks
Number of subjects: 95

Group type: COMPARATOR
Intervention: Untreated hypertensive patients
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Treated hypertensive patients
Number of subjects: 95
Study: 24149930

Group type: EXPERIMENTAL
Intervention: Gastroretentive gabapentin (G‐GR) 600 mg am/1,200 mg pm
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Gastroretentive gabapentin (G‐GR)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 22215656

Group type: EXPERIMENTAL
Intervention: BicaVera solution (bicarbonate/low-GDP PD solution)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard PD fluid (lactate-buffered standard PD fluid)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: BicaVera solution
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard PD fluid
Number of subjects: 31
Study: 19887019

Group type: EXPERIMENTAL
Intervention: Sarcosine (2 g/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: D-serine (2 g/d)
Number of subjects: 60
Study: 18036483

Group type: EXPERIMENTAL
Intervention: Ethical considerations in psychiatric research
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluation of research protocols
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized controlled treatment trials
Number of subjects: 0
Study: 15759147

Group type: EXPERIMENTAL
Intervention: Oral administration of radioiodide
Number of subjects: 114

Group type: COMPARATOR
Intervention: Intravenous administration of radioiodide
Number of subjects: 114
Study: 11811645

Group type: EXPERIMENTAL
Intervention: Selective dorsal rhizotomy plus physiotherapy (SDR+PT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Physiotherapy without selective dorsal rhizotomy (PT-only)
Number of subjects: 90
Study: 10606875

Group type: EXPERIMENTAL
Intervention: 0.5 g/kg b.w. IVIg (group A)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 1 g/kg b.w. IVIg (group B)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 1.5 g IVIg/kg b.w. (for initial non-responders in group A)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 1 g IVIg/kg b.w. (for initial non-responders in group B)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups (overall)
Number of subjects: 37
Study: 8955434

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1826984

Group type: EXPERIMENTAL
Intervention: Tuna (n-3 fatty acids)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fish oil (n-3 fatty acids)
Number of subjects: 10
Study: 7039242

Group type: EXPERIMENTAL
Intervention: Cyclofenil
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 29939328

Group type: EXPERIMENTAL
Intervention: Framed messages emphasizing contributions of older adults to society
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Framed messages emphasizing aging as a process of accumulating wisdom and energy
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Framed messages discussing mechanisms of prejudice against older adults
Number of subjects: 767

Group type: COMPARATOR
Intervention: Unframed message about aging
Number of subjects: 767

Group type: COMPARATOR
Intervention: Control message unrelated to aging
Number of subjects: 767
Study: 28158151

Group type: EXPERIMENTAL
Intervention: 0.625% capsaicin patch (CP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.075% capsaicin cream
Number of subjects: 60

Group type: COMPARATOR
Intervention: Repetitive patch application (0.625% CP and 0.075% capsaicin cream)
Number of subjects: 60
Study: 25176271

Group type: EXPERIMENTAL
Intervention: Primary preventive ICD implantation
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 33
Study: 22723570

Group type: EXPERIMENTAL
Intervention: bupropion
Number of subjects: 174

Group type: COMPARATOR
Intervention: escitalopram
Number of subjects: 174

Group type: COMPARATOR
Intervention: fatigue-free subjects
Number of subjects: 174
Study: 21215637

Group type: EXPERIMENTAL
Intervention: Comfortably secured laces
Number of subjects: 20

Group type: COMPARATOR
Intervention: Loosened laces
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Looser lacing techniques
Number of subjects: 20
Study: 18304334

Group type: EXPERIMENTAL
Intervention: Peer mentor support (two-weekly contact tailored to individual needs)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Peer mentor support
Number of subjects: 11
Study: 17039655

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 7
Study: 15369915

Group type: EXPERIMENTAL
Intervention: Checklist format
Number of subjects: 32

Group type: COMPARATOR
Intervention: Global rating form
Number of subjects: 32
Study: 10741298

Group type: EXPERIMENTAL
Intervention: Epirubicin 40 mg/m2 intravenous push, Docetaxel 75 mg/m2 in 1 h infusion, Cisplatin 75 mg/m2 with pre‐ and posthydration, treatment repeated every 21 days
Number of subjects: 30
Study: 9095231

Group type: EXPERIMENTAL
Intervention: Conventional immunotherapy with natural pollen extract
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bet v 1 d isoform
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naturally occurring pollen Bet v 1 isoforms
Number of subjects: 0
Study: 1396370

Group type: EXPERIMENTAL
Intervention: Lidocaine spray (80-120 mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 3907933

Group type: EXPERIMENTAL
Intervention: Hexabrix 320
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conray 280
Number of subjects: 97
Study: 30792050

Group type: EXPERIMENTAL
Intervention: Horticultural activity program (8 weeks)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 150
Study: 29360915

Group type: EXPERIMENTAL
Intervention: eGFR decline below cohort median (-1.28 ml/minute/1.73 m2/2 years)
Number of subjects: 20207

Group type: EXPERIMENTAL
Intervention: 5 ml/min/1.73 m2/year eGFR decline
Number of subjects: 20207

Group type: EXPERIMENTAL
Intervention: Long-term mortality association
Number of subjects: 20207
Study: 27053273

Group type: EXPERIMENTAL
Intervention: Adapted NAP SACC UK intervention
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study: 25898077

Group type: EXPERIMENTAL
Intervention: Health-promoting programme implemented in treatment schools
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health-promoting programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (schools not implementing the programme)
Number of subjects: 0
Study: 23672321

Group type: EXPERIMENTAL
Intervention: Compression shirt with the straps fully tensioned (S + T)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Compression shirt with no strap tension (S)
Number of subjects: 38
Study: 20186629

Group type: EXPERIMENTAL
Intervention: Methylene blue perfusion via superior rectal artery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no methylene blue perfusion)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Methylene blue group
Number of subjects: 20
Study: 18467721

Group type: EXPERIMENTAL
Intervention: Extended-dose temozolomide (TMZ) 75 mg/m²/d for 6 weeks followed by a 2-week rest period
Number of subjects: 49
Study: 17062260

Group type: EXPERIMENTAL
Intervention: Esophagogastrectomy with wrapping of the pedicled omentum around the esophagogastric anastomosis (Group A)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Esophagogastrectomy without using the omental graft (Group B)
Number of subjects: 194
Study: 12760997

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (COPA)
Number of subjects: 36
Study: 11535970

Group type: EXPERIMENTAL
Intervention: Neltenexine (1 sachet thrice daily for 20 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sobrerol (1 sachet thrice daily for 20 days)
Number of subjects: 30
Study: 9489902

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily for 1 week
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 7530124

Group type: EXPERIMENTAL
Intervention: Transrectal ultrasound (TRUS)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Drug-induced changes
Number of subjects: 21
Study: 3137066

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (1 microgram kg‐1 min‐1)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 14
Study: 31879996

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (measured in pack-years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed IV analysis method using semiparametric linear transformation models
Number of subjects: 0
Study: 29663129

Group type: EXPERIMENTAL
Intervention: Full Cogmed training program (25 sessions, 40 minutes each)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abbreviated Cogmed program (25 sessions, 20 minutes each)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 0
Study: 27973684

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid injection (sodium hyaluronate)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Arthrocentesis with 0.9% NaCl solution (SS)
Number of subjects: 24
Study: 26359007

Group type: EXPERIMENTAL
Intervention: ΔBNP% in weaning success group (group C)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: ΔBNP in weaning success group (group C)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: ROC curve analysis of ΔBNP%
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: ROC curve analysis of ΔBNP
Number of subjects: 56
Study: 23829159

Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Exercise (HIIE) 3 times per week, 20 min per session for 12 weeks
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Exercise (HIIE)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 21438989

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 3320

Group type: EXPERIMENTAL
Intervention: Topiramate (96-200 mg/day)
Number of subjects: 3320
Study: 19074546

Group type: EXPERIMENTAL
Intervention: Voxel-based morphometry (VBM) analysis in HD patients
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy controls (133 subjects)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy controls (99 subjects)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy controls (66 subjects)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy controls (33 subjects)
Number of subjects: 22
Study: 17125496

Group type: EXPERIMENTAL
Intervention: artesunate + SP (AS+SP)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: artesunate + amodiaquine (AS+AQ)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: artemether + lumefantrine (AL)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Comparison of AS+SP to AL
Number of subjects: 298

Group type: COMPARATOR
Intervention: Comparison of AS+AQ to AL
Number of subjects: 298

Group type: COMPARATOR
Intervention: Comparison of all groups
Number of subjects: 298
Study: 14744844

Group type: EXPERIMENTAL
Intervention: Restless Legs Syndrome (RLS)
Number of subjects: 4310

Group type: EXPERIMENTAL
Intervention: Parity (number of children)
Number of subjects: 4310

Group type: COMPARATOR
Intervention: Quality of life
Number of subjects: 4310
Study: 11703422

Group type: EXPERIMENTAL
Intervention: Miglitol (25 mg t.i.d. for 4 weeks, 50 mg t.i.d. for 12 weeks, 100 mg t.i.d. for 16 weeks)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Miglitol combined with metformin
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo combined with metformin
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Miglitol/metformin
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo/metformin
Number of subjects: 152
Study: 9206278

Group type: EXPERIMENTAL
Intervention: Camera 2 (three-chip camera)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Camera 1 (single-chip camera)
Number of subjects: 130
Study: 8190572

Group type: EXPERIMENTAL
Intervention: Carnitine (100 mg/kilo)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 30459160

Group type: EXPERIMENTAL
Intervention: Risk-stratified treatment approaches in major international cooperative groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current therapies for infant leukemia
Number of subjects: 0
Study: 30051222

Group type: EXPERIMENTAL
Intervention: Community pharmacist's interventions
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no pharmacist intervention)
Number of subjects: 140
Study: 27059833

Group type: EXPERIMENTAL
Intervention: Stabilization exercises focusing on pelvic floor muscles (12 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine physiotherapy modalities and regular exercises (Control)
Number of subjects: 60
Study: 25085407

Group type: EXPERIMENTAL
Intervention: Chlorhexidine solution
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control group (distilled water)
Number of subjects: 187
Study: 22853847

Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg/Amlodipine 5 mg (I300/A5)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Irbesartan 300 mg (I300)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Irbesartan 150 mg (I150)
Number of subjects: 320
Study: 20929124

Group type: EXPERIMENTAL
Intervention: Astragalus granule (2.25 g twice a day for two weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard treatment for correcting heart failure (including digoxin, diuretics)
Number of subjects: 45
Study: 18761785

Group type: EXPERIMENTAL
Intervention: VAL80/HCTZ12.5 mg
Number of subjects: 1175

Group type: COMPARATOR
Intervention: VAL80 mg
Number of subjects: 1175
Study: 15834030

Group type: EXPERIMENTAL
Intervention: Sildenafil (25‐100 mg)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study: 12027831

Group type: EXPERIMENTAL
Intervention: Chronic intracranial hypertension (ICH) patients
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal data from 16 age‐matched, healthy subjects
Number of subjects: 16
Study: 10360500

Group type: EXPERIMENTAL
Intervention: Color-coded Doppler sonography (CCDS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Micturating cystography (MC)
Number of subjects: 48
Study: 7497559

Group type: EXPERIMENTAL
Intervention: Caffeine tablets equal to individual average daily caffeine consumption
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1742450

Group type: EXPERIMENTAL
Intervention: Adaptive weighted log-rank statistic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unweighted log-rank statistic
Number of subjects: 0
Study: 7210779

Group type: EXPERIMENTAL
Intervention: 60 mg of diltiazem (D)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 mg of nifedipine (N)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison between D and N
Number of subjects: 10
Study: 30690333

Group type: EXPERIMENTAL
Intervention: Internet use frequency, preferred online activities, Facebook interactions, online risk behaviors (cyberbullying and sexting)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Facebook usage
Number of subjects: 58
Study: 30171914

Group type: EXPERIMENTAL
Intervention: Expectancy of receiving chocolate (0%, 50%, 100%)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hungry condition
Number of subjects: 120

Group type: COMPARATOR
Intervention: Satiated condition
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Self-perceived food addiction (SPFA)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Desire-to-eat (DtE) chocolate
Number of subjects: 120
Study: 26994381

Group type: EXPERIMENTAL
Intervention: LaVita multivitamin and trace element composition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 25407957

Group type: EXPERIMENTAL
Intervention: Exercise training group (EG)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 35
Study: 22146289

Group type: EXPERIMENTAL
Intervention: SMS supplemented with phone interviews
Number of subjects: 133

Group type: COMPARATOR
Intervention: SMS alone
Number of subjects: 133